Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This study tests whether a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) works better than the current standard treatment (tislelizumab plus chemotherapy) for people with advanced or metastatic non-small cell lung cancer who have not had prior treatment. Abou…

This study tests whether adding the experimental drug SHR-A2009 to the standard pill aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 adults who have not had prior treatment for their advanc…

This study tests an experimental drug called SHR-1681 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the…

This study tests a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) against the current standard treatment for advanced biliary tract cancer that has not been treated before. About 604 adults with inoperable cancer will take part. The goal is to see if the new c…

This study tests a new drug, SHR-A1811, combined with standard chemotherapy (carboplatin and bevacizumab) in people whose ovarian cancer has returned after initial treatment but still responds to platinum-based drugs. The goal is to find the safest dose and see how well the combi…

This study tests a new drug called SHR-4849 combined with other cancer medicines in people with advanced solid tumors. The goal is to see if the combination is safe and can shrink tumors. About 120 adults aged 18 to 75 with measurable tumors and adequate organ function are eligib…

This study tests a new drug called SHR-8068 combined with other cancer treatments for people with colorectal cancer. The goal is to see if the combination is safe and helps shrink or control tumors. About 200 adults aged 18 to 75 with good performance status are being recruited.

This study tests a new drug, SHR-A2102, against standard chemotherapy in about 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and immunotherapy. The goal is to see if SHR-A2102 helps people live longer. Participants must hav…

This early-phase study tests a new injection called SHR-3821 in 162 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Participants must be 18-75, in …

This early-phase study tests a new drug called SHR-A1811(sc) given as a shot under the skin for people with solid tumors. The main goals are to see how the drug moves through the body, if it is safe, and if it helps shrink tumors. About 107 adults with advanced solid tumors will …

This early-stage study tests an experimental drug called SHR-7782 in 200 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow their growth. Participants must have…

This early-stage study tests a new drug called SHR-4506 in about 102 adults with advanced malignant tumors who have run out of standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the disease. Participants rece…

This study tests a new drug called SHR-A1811 combined with chemotherapy and/or immunotherapy for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if the combination is safe and shrinks tumors. About 258 adults aged 18-75 who have …

This early-stage trial tests a new drug (SHR-2524) combined with bevacizumab in 36 adults with advanced liver cancer that cannot be removed by surgery. Participants have not had prior cancer treatment. The study focuses on safety and how the drugs move through the body, not on cu…

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can help shrink tumors in people with stomach or gastroesophageal junction cancer. About 200 adults who have not had prior treatment for their cancer will receive one …

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors. The goal is to find safe doses and see if the combination can shrink tumors. About 876 adults aged 18-75 with advanced cancer that has not responded to standar…

This study tests whether a new drug combination (SHR-A1811 plus chemotherapy and adebrelimab) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. About 600 adults aged 18 to 75 wil…

This study tests whether a new combination of two drugs (SHR-A1811 and SHR-1316) works better than the current standard treatment for people with a certain type of advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 400 women aged 18-75 w…

This study tests an experimental drug called SHR-1826 in 90 people with advanced or spreading non-small cell lung cancer who have already tried other treatments. Participants receive the drug by IV every three weeks. The goal is to see if the drug can shrink tumors and how safe i…

This study tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) helps people with diffuse large B-cell lymphoma whose cancer has come back or not responded to prior treatment. About 280 adults aged 18–79 will be randomly assigned to receive eith…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study tests whether adding two experimental drugs (adebrelimab and SHR-8068) to standard chemoradiation helps shrink locally advanced rectal cancer before surgery. About 165 adults aged 18-75 with resectable tumors who haven't had prior treatment will participate. The main g…

This study tests a new drug called SHR-9839 combined with other anti-tumor treatments for people with advanced solid tumors. The goal is to see if the combination is safe and helps shrink or control tumors. About 70 adults aged 18-70 with measurable tumors and good performance st…

This study compares a new combination of two drugs (SHR-A2102 and adebrelimab) against standard chemotherapy for people with advanced bladder cancer that has spread and hasn't been treated before. About 462 adults aged 18 to 80 will take part. The goal is to see if the new combo …

This study tests a new three-drug combination (SHR-8068, adebrelimab, and bevacizumab) against standard two-drug treatments for advanced liver cancer that cannot be removed by surgery. About 590 adults with this type of cancer will participate. The goal is to see if the new combo…

This study tests a combination of three drugs (SHR-8068, adebrelimab, and others) in 139 adults with advanced kidney cancer that cannot be removed by surgery or has spread. The goal is to see if the treatment can shrink tumors and control the disease. Participants must provide a …

This study tests a new drug, SHR-A1904, in people with advanced bile duct cancer that has not responded to previous treatments. The drug targets a specific protein (CLDN18.2) on cancer cells. About 151 participants will receive the drug to see if it can shrink tumors or slow dise…

This study tests an experimental drug called SHR-2017 in 210 adults with solid tumors that have spread to the bones. The goal is to see if it can reduce pain and prevent bone problems like fractures or the need for radiation or surgery. Participants will receive either SHR-2017 o…

This study tests a new drug called SHR-4375 combined with other cancer treatments in 198 adults with advanced solid tumors that have not responded to standard care. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth. Participants must…

This early-stage study tests a single dose of the experimental drug SHR-1894 in 40 healthy adults to check its safety and how the body processes it. Participants receive either the drug or a placebo by injection. The goal is to gather basic safety information, not to treat any di…